RayBiotech (RBI) has executed a master services and supply agreement with the Proteomics and Metabolomics Core Facility of Colorado State University in Fort Collin, Colorado.
Under the deal, RayBiotech will offer biomarker discovery and characterization services and products to Colorado State University researchers located campus-wide.
The services and products, which will be based upon RayBiotech's antibody array and ELISA technologies, will be provided under preferred pricing arrangements.
The company said that all services will be executed under Good Laboratory Practices (GLP) compliance and all products are manufactured under Good Manufacturing Practices (GMP) compliance and ISO 13485: 2003 certification.
RayBiotech president, co-founder and chief operating officer Rani Huang said the Proteomics and Metabolomics Core Facility at Colorado State University is one of the leading biochemical pathway characterization cores nationwide.
"We are delighted to have the opportunity to provide comprehensive biomarker analysis services and products to the CSU Core under preferred pricing, and we look forward to making a significant impact on biomarker characterization efforts by all CSU researchers," Huang said.
Colorado State University director of the Proteomics and Metabolomics Core Jessica Prenni said, "RayBiotech's portfolio of antibody array and ELISA-related services and products perfectly complements the objectives of our core facility."